Xilio Therapeutics CFO Salvatore Giovine resigns effective Aug 19, 2022

Xilio Therapeutics, Inc.

CFO Salvatore Giovine resigned for personal family reasons, effective August 19, 2022.
No successor or interim CFO was announced in this filing.
Giovine served as principal financial officer of the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Salvatore Giovine

chief financial officer

XLO · Xilio Therapeutics, Inc.

Effective: 2022-08-19
Filed: July 28, 2022, 7:59 PM ET

On July 25, 2022, Salvatore Giovine notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer (principal financial officer) of the Company, effective August 19, 2022, for personal family reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Salvatore Giovine resigned as chief financial officer at Xilio Therapeutics, Inc..

Action: resigned
Role: chief financial officer

Exact text from the filing

On July 25, 2022, Salvatore Giovine notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer (principal financial officer) of the Company, effective August 19, 2022, for personal family reasons.

View on SEC.gov

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-011295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.